C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $39.63
    +0.51 (+1.30%)

    Market Cap: $3.07B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    -4.18%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.01
    Range$-1.07 - $-0.94
    11 analysts
    EPS Revisions
    6
    0
    7d
    5
    1
    30d
    EPS Estimate Drift
    90d ago$-1.08-7.4%
    60d ago$-1.08-7.4%
    30d ago$-1.08-7.6%
    7d ago$-1.08-7.1%
    Current$-1.01
    Revenue Consensus
    $870900
    Range$0 - $3M
    10 analysts
    Dec 31, 2026
    EPS Consensus$-0.91
    Range$-1.14 - $-0.51
    11 analysts
    Revenue Consensus
    $-566190
    Range$-2554280 - $4M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.91---
    Sep 26EST
    		-$-1.01---
    Jun 26
    		$-0.94$-1.04+9.62%Beat-10.6%
    Mar 26
    		$-1.18$-1.13-4.42%Miss-45.7%
    Dec 25
    		$-1.22$-1.00-22.00%Miss-71.8%
    Sep 25
    		$-1.01$-0.89-13.48%Miss-57.8%
    Jun 25
    		$-0.85$-0.86+1.16%Beat-57.4%
    Mar 25
    		$-0.81$-0.74-9.46%Miss-44.6%
    Dec 24
    		$-0.71$-0.71+0.64%Beat+14.5%
    Sep 24
    		$-0.64$-0.67+4.48%Beat+21.0%
    Jun 24
    		$-0.54$-0.59+8.47%Beat+16.9%
    Mar 24
    		$-0.56$-0.67+16.42%Beat+9.7%
    Dec 23
    		$-0.83$-0.74-12.16%Miss-48.2%
    Sep 23
    		$-0.81$-0.66-22.73%Miss-42.1%
    Jun 23
    		$-0.65$-0.66+1.52%Beat-12.1%
    Mar 23
    		$-0.62$-0.60-3.33%Miss-24.0%
    Dec 22
    		$-0.56$-0.59+5.08%Beat-30.2%
    Sep 22
    		$-0.57$-0.57+0.00%Beat-54.1%
    Jun 22
    		$-0.58$-0.42-38.10%Miss-70.6%
    Mar 22
    		$-0.50$-0.43-16.28%Miss-19.0%
    Dec 21
    		$-0.43$-0.42-2.38%Miss+21.8%
    Sep 21
    		$-0.37$-0.35-5.71%Miss-2.8%
    Jun 21
    		$-0.34$-0.40+15.00%Beat+40.4%
    Mar 21
    		$-0.42$-0.37-13.51%Miss+42.5%
    Dec 20
    		$-0.55$-0.37-48.65%Miss+14.1%
    Sep 20
    		$-0.36$-0.38+5.26%Beat+52.0%
    Jun 20
    		$-0.57$-0.58+1.72%Beat+32.1%
    Mar 20
    		$-0.73$-0.72-1.39%Miss+47.9%
    Dec 19
    		$-0.64$-0.90+28.89%Beat+21.0%
    Sep 19
    		$-0.75$-0.84+10.71%Beat-25.0%
    Jun 19
    		$-0.84$-1.17+28.21%Beat+49.1%
    Mar 19
    		$-1.40$-1.14-22.81%Miss+88.9%
    Dec 18
    		$-0.81$-1.20+32.50%Beat+68.2%
    Sep 18
    		$-0.60N/A+76.47%Beat+80.0%
    Jun 18
    		$-1.65$-2.70+38.89%Beat+52.2%
    Mar 18
    		$-12.60$-3.03-315.84%Miss-200.0%
    Dec 17
    		$-2.55$-3.71+31.27%Beat+43.3%
    Sep 17
    		$-3.00$-4.01+25.19%Beat+31.0%
    Jun 17
    		$-3.45$-4.17+17.27%Beat-
    Mar 17
    		$-4.20$-4.31+2.55%Beat-
    Dec 16
    		$-4.50$-5.04+10.71%Beat-
    Sep 16
    		$-4.35$-5.00+13.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-9.11EV/EBITDA-17.34x
    Price/FCF-12.74xFCF Yield-7.85%
    Profitability
    Profit Margin0.00%Operating Margin-366468.00%
    ROE-43.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio11.82xQuick Ratio11.82x
    Trading Statistics
    Beta0.84Avg Volume838.62K
    52-Week High$45.1452-Week Low$21.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$40.54
    SMA 20$41.37
    SMA 50$38.54
    SMA 200$31.27
    EMA 10$40.42
    EMA 20$40.33
    EMA 50$38.44
    EMA 200$32.39

    MACD

    Line: 0.48Signal: 0.96Hist: -0.48

    ADX

    ADX: 20.6+DI: 20.3-DI: 23.7

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down4.0
    PSAR$43.37

    Bollinger Bands

    Upper Band$44.45
    Lower Band$38.30
    %B Position1486%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    48.3

    Momentum Oscillators

    Stoch %K11.0
    Stoch %D15.6
    Williams %R-86.1
    ROC (10d)-5.5%
    Momentum-2.29
    CCI (20d)-112.9
    MFI (14d)46.2

    Volatility Measures

    ATR (14d)$1.60(4.0%)
    StdDev (20d)1.54
    Hist Vol40.7%(High)

    Volume Flow

    VWAP$39.40
    OBV546.8K
    AD Line10.0M
    CMF (20d)0.089

    Volume Metrics

    Avg Vol (20d)798.8K
    Vol Ratio0.9x
    VWMA (20d)$41.60

    Pivot Points

    R3$41.64
    R2$41.11
    R1$40.11
    Pivot Point$39.58
    S1$38.58
    S2$38.05
    S3$37.05

    Advanced Oscillators

    TSI9.72
    Ultimate Osc42.4
    KST77.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$22,000$15,000$120,000$0$730,000$695,000$1.18M$3.19M$2.50M$156,000$4.13M$1.52M
    Cost of Revenue$0$0N/A$0$0$0$819,000$0$0$0$30.43M$0
    Gross Profit$22,000$15,000$120,000$0$730,000$695,000$1.18M$3.19M$2.50M$156,000$4.13M$1.52M
    Operating Expenses$80.64M$84.45M$87.27M$73.62M$64.59M$63.43M$57.20M$55.32M$48.81M$40.76M$51.76M$42.76M
    R&D$67.54M$73.00M$75.33M$62.93M$54.20M$52.61M$46.94M$45.26M$39.69M$31.66M$30.43M$34.53M
    SG&A$13.10M$11.45M$11.94M$10.69M$10.39M$10.82M$10.26M$10.05M$9.13M$9.10M$8.83M$8.22M
    Operating Income$-80,623,000$-84,435,000$-87,154,000$-73,617,000$-63,857,000$-62,739,000$-56,027,000$-52,126,000$-46,317,000$-40,608,000$-47,627,000$-41,239,000
    Interest Income$7.12M$5.75M$5.84M$6.57M$7.26M$8.94M$8.94M$10.01M$10.47M$7.80M$4.32M$2.98M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$93.80M$0
    Income Before Tax$-73,503,000$-78,685,000$-81,317,000$-67,044,000$-56,600,000$-53,796,000$-47,092,000$-42,121,000$-35,842,000$-32,808,000$-141,429,000$0
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-73,503,000$-78,685,000$-81,317,000$-67,044,000$-56,600,000$-53,796,000$-47,092,000$-42,121,000$-35,842,000$-32,808,000$-43,306,000$-38,260,000
    EBITDA$-81,419,000$-84,211,000$-87,220,000$-73,811,000$-64,672,000$-64,139,000$-58,571,000$-55,673,000$-50,260,000$-43,146,000$-49,047,000$-42,099,000
    EBIT$-80,623,000$-84,435,000$-87,154,000$-73,617,000$-63,857,000$-62,739,000$-56,027,000$-52,126,000$-46,317,000$-40,608,000$-47,627,000$-41,239,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLDX

    News

    Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX

    Celldex Therapeutics, Inc. (NASDAQ:CLDX) generated $1.54 million USD in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment. This figure represents a decrease from the $7.02 million USD reported the previous year. The United States was the largest contributor to the company's revenue, mirroring the overall revenue figures.

    TradingView•8/21/26•
    Somewhat-Bearish

    Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts

    Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.08, exceeding its current share price of $41.70. While recent analyst actions were mixed, including Guggenheim raising its target to $100 and Cantor Fitzgerald cutting its target to $61, the overall sentiment remains positive. The company reported a quarterly loss of $0.94 per share, beating expectations, but revenue of $0.02 million missed estimates significantly.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE

    Bank of America Corp DE significantly increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 70.8% in the first quarter, now owning 708,647 shares valued at $22.5 million. This comes as Celldex, a clinical-stage biopharmaceutical company, reported a smaller-than-expected quarterly loss of $0.94 per share. Analysts maintain a "Moderate Buy" consensus rating for CLDX, with an average price target of $55.46.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

    Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a SCHEDULE 13G/A, indicates that no single entity among the reporting persons holds sole voting or dispositive power over these shares.

    Stock Titan•8/14/26•
    Neutral

    T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

    T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 shares. Despite the disclosure, T. Rowe Price Associates explicitly states that this report should not be interpreted as an admission of beneficial ownership.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About CLDX

    Does CLDX pay dividends?
    Celldex Therapeutics Inc (CLDX) does not currently pay a regular dividend.
    What is CLDX's market cap?
    Celldex Therapeutics Inc (CLDX) has a market capitalization of $3.07B with a current stock price of $39.63.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In